Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Aug 12, 2023
Regulation

Aug. 11 Quick Takes: Janssen gains prostate cancer approval

Plus: Atreca scraps lead program, turns to ADCs and updates from ALX Oncology, Hansoh-Antengene, Foghorn, Galera, Cascade  
BioCentury | Mar 16, 2022
Deals

March 15 Quick Takes: Blackstone backs Sanofi’s multiple myeloma trial

Plus: Keytruda, Lynparza combo misses, pandemic antiviral initiative launches and updates from Eisai, Biogen and more
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

Who's doing what in next-generation targeted radiotherapies for cancer
BioCentury | Feb 6, 2019
Distillery Therapeutics

Cancer

BioCentury | Dec 4, 2018
Distillery Therapeutics

Cancer

BioCentury | Nov 30, 2018
Company News

CAFC denies J&J's Zytiga patent protection appeal

BioCentury | Sep 14, 2018
Emerging Company Profile

Laekna’s jumping off place

Why Laekna Therapeutics opted to start with a trio of Novartis compounds
BioCentury | May 30, 2018
Distillery Therapeutics

Cancer

Items per page:
1 - 10 of 165